LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Report Describes Mechanism Underlying Genetic Eye Disease

By Gerald M. Slutzky, PhD
Posted on 15 Nov 2016
Image: The XLRS is caused by mutations in the retinal protein retinoschisin. The protein plays a crucial role in the cellular organization of the retina, assembling itself to form paired octameric (consisting of eight retinoschisin) rings. The rings each resemble an eight-bladed propeller (Photo courtesy of the University of Manchester).
Image: The XLRS is caused by mutations in the retinal protein retinoschisin. The protein plays a crucial role in the cellular organization of the retina, assembling itself to form paired octameric (consisting of eight retinoschisin) rings. The rings each resemble an eight-bladed propeller (Photo courtesy of the University of Manchester).
The molecular mechanism responsible for the genetic eye disease X-linked Retinoschisis (XLRS), which leads to a type of macular degeneration in which the inner layers of the retina split causing severe loss of vision and gradual blindness, was described in a recent publication.

XLRS is caused by a mutation in retinoschisin, an octameric retinal-specific protein that is essential for the maintenance of the retinal architecture. Investigators at the University of Manchester (United Kingdom) investigated the structure of the retinoschisin monomer and the impact of two XLRS-causing mutants using a combinatorial approach of biophysics and cryo-EM. Cryo-electron microscopy (cryo-EM) allows the observation of specimens that have not been stained or fixed in any way, showing them in their native environment while integrating multiple images to form a three-dimensional model of the sample.

The investigators reported in the October 23, 2016, online edition of the journal Human Molecular Genetics that the retinoschisin monomer had an elongated structure, which persisted in the octameric assembly. Retinoschisin formed a dimer of octamers with each octameric ring adopting a planar propeller structure. Comparison of the octamer with the hexadecamer structure indicated little conformational change in the retinoschisin octamer upon dimerization, suggesting that the octamer provided a stable interface for construction of the hexadecamer.

The H207Q XLRS-associated mutation was found in the interface between octamers and destabilized both monomeric and octameric retinoschisin. Octamer dimerization was consistent with the adhesive function of retinoschisin supporting interactions between retinal cell layers, so disassembly would prevent structural coupling between opposing membranes. In contrast, cryo-EM structural analysis of the R141H mutation at approximately 4.2 angstrom resolution was found to only cause a subtle conformational change in the propeller tips, potentially perturbing an interaction site.

"We found that one disease-causing mutation sits in the interface between the octamer rings, causing retinoschisin to be less stable," said senior author Dr. Clair Baldock, professor of biochemistry at The University of Manchester. "The other mutation is on the propeller tip which we think is a novel interaction site for other binding proteins in the retina. XLRS is a promising candidate for gene therapy, so our findings on these two different classes of mutations will be informative for future therapeutic strategies."

Related Links:
University of Manchester


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more